285 related articles for article (PubMed ID: 21983157)
61. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.
Pichyangkul S; Gettayacamin M; Miller RS; Lyon JA; Angov E; Tongtawe P; Ruble DL; Heppner DG; Kester KE; Ballou WR; Diggs CL; Voss G; Cohen JD; Walsh DS
Vaccine; 2004 Sep; 22(29-30):3831-40. PubMed ID: 15364429
[TBL] [Abstract][Full Text] [Related]
62. BCG promotes cord blood monocyte-derived dendritic cell maturation with nuclear Rel-B up-regulation and cytosolic I kappa B alpha and beta degradation.
Liu E; Law HK; Lau YL
Pediatr Res; 2003 Jul; 54(1):105-12. PubMed ID: 12672905
[TBL] [Abstract][Full Text] [Related]
63. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein.
Nardin EH; Calvo-Calle JM; Oliveira GA; Clavijo P; Nussenzweig R; Simon R; Zeng W; Rose K
Vaccine; 1998 Apr; 16(6):590-600. PubMed ID: 9569470
[TBL] [Abstract][Full Text] [Related]
64. Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.
Speake C; Pichugin A; Sahu T; Malkov V; Morrison R; Pei Y; Juompan L; Milman N; Zarling S; Anderson C; Wong-Madden S; Wendler J; Ishizuka A; MacMillen ZW; Garcia V; Kappe SH; Krzych U; Duffy PE
PLoS One; 2016; 11(7):e0159449. PubMed ID: 27434123
[TBL] [Abstract][Full Text] [Related]
65. Lactoferrin modulation of BCG-infected dendritic cell functions.
Hwang SA; Actor JK
Int Immunol; 2009 Oct; 21(10):1185-97. PubMed ID: 19692539
[TBL] [Abstract][Full Text] [Related]
66. Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated Adults.
Szpakowski P; Biet F; Locht C; Paszkiewicz M; Rudnicka W; Druszczyńska M; Allain F; Fol M; Pestel J; Kowalewicz-Kulbat M
J Immunol Res; 2015; 2015():359153. PubMed ID: 26339658
[TBL] [Abstract][Full Text] [Related]
67. Use of a tuberculin purified protein derivative--Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guérin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants.
Lussow AR; Del Giudice G; Rénia L; Mazier D; Verhave JP; Verdini AS; Pessi A; Louis JA; Lambert PH
Proc Natl Acad Sci U S A; 1990 Apr; 87(8):2960-4. PubMed ID: 2183219
[TBL] [Abstract][Full Text] [Related]
68. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM
PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295
[TBL] [Abstract][Full Text] [Related]
69. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif.
Bruna-Romero O; Rocha CD; Tsuji M; Gazzinelli RT
Vaccine; 2004 Sep; 22(27-28):3575-84. PubMed ID: 15315836
[TBL] [Abstract][Full Text] [Related]
70. A malaria vaccine candidate based on a hepatitis B virus core platform.
Sällberg M; Hughes J; Jones J; Phillips TR; Milich DR
Intervirology; 2002; 45(4-6):350-61. PubMed ID: 12602355
[TBL] [Abstract][Full Text] [Related]
71. Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and adenovirus (Ad5) immune mice.
Schuldt NJ; Aldhamen YA; Godbehere-Roosa S; Seregin SS; Kousa YA; Amalfitano A
Malar J; 2012 Jun; 11():209. PubMed ID: 22720732
[TBL] [Abstract][Full Text] [Related]
72. The influence of interferon-β supplemented human dendritic cells on BCG immunogenicity.
El-Sahrigy SAF; Rahman AMOA; Samaha DY; Mohamed NA; Saber SM; Talkhan HA; Ismail GA; Ibraheem EM; Riad EM
J Immunol Methods; 2018 Jun; 457():15-21. PubMed ID: 29522775
[TBL] [Abstract][Full Text] [Related]
73. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
74. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
[TBL] [Abstract][Full Text] [Related]
75. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
[TBL] [Abstract][Full Text] [Related]
76. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein.
Persson C; Oliveira GA; Sultan AA; Bhanot P; Nussenzweig V; Nardin E
J Immunol; 2002 Dec; 169(12):6681-5. PubMed ID: 12471098
[TBL] [Abstract][Full Text] [Related]
77. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
[TBL] [Abstract][Full Text] [Related]
78. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
[TBL] [Abstract][Full Text] [Related]
79. Murine Splenic Natural Killer Cells Do Not Develop Immunological Memory after Re-Encounter with Mycobacterium bovis BCG.
Kawahara M; Hasegawa N; Takaku H
PLoS One; 2016; 11(3):e0152051. PubMed ID: 26999357
[TBL] [Abstract][Full Text] [Related]
80. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
